Emmaus Life Sciences (Emmaus Life Sciences) Debt-to-Revenue : 1.76 (As of Sep. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Emmaus Life Sciences Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Emmaus Life Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $29.71 Mil. Emmaus Life Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $5.63 Mil. Emmaus Life Sciences's annualized Revenue for the quarter that ended in Sep. 2023 was $20.07 Mil. Emmaus Life Sciences's annualized Debt-to-Revenue for the quarter that ended in Sep. 2023 was 1.76.

Emmaus Life Sciences Debt-to-Revenue Historical Data

The historical data trend for Emmaus Life Sciences's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Emmaus Life Sciences Debt-to-Revenue Chart

Emmaus Life Sciences Annual Data

Trend

Sep13

Sep14

Sep15

Sep16

Sep17

Sep18

Dec19

Dec20

Dec21

Dec22

Debt-to-Revenue

Get a 7-Day Free Trial

0.45

0.86

0.82

1.09

1.68

Emmaus Life Sciences Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Debt-to-Revenue	Get a 7-Day Free Trial															1.73	1.30	1.34	0.86	1.76

Competitive Comparison of Emmaus Life Sciences's Debt-to-Revenue

For the Biotechnology subindustry, Emmaus Life Sciences's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Emmaus Life Sciences's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Emmaus Life Sciences's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Emmaus Life Sciences's Debt-to-Revenue falls into.

Emmaus Life Sciences Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Emmaus Life Sciences's Debt-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(24.539	+	6.279)	/	18.39
	=	1.68

Emmaus Life Sciences's annualized Debt-to-Revenue for the quarter that ended in Sep. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(29.71	+	5.626)	/	20.072
	=	1.76

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2023) Revenue data.

Emmaus Life Sciences Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Emmaus Life Sciences's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Emmaus Life Sciences (Emmaus Life Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Emmaus Life Sciences Inc (OTCPK:EMMA) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

21250 Hawthorne Boulevard, Suite 800, Torrance, CA, USA, 90503

Website

https://www.emmausmedical.com

Emmaus Life Sciences Inc is a biopharmaceutical company engaged in the discovery, development, and commercialization of new treatments and therapies primarily for rare and orphan diseases. The company's commercial product is Endari, an oral pharmaceutical grade L-glutamine treatment indicated to reduce acute complications of sickle cell disease in adult and pediatric patients five years of age and older. Its products in the pipeline include Diverticulosis and Cell Sheet Engineering.

Executives

Seah H. Lim	director	21250 HAWTHORNE BLVD., SUITE 800, TORRANCE CA 90503
Willis C Lee	director, officer: Vice Chairman & COO	20725 S. WESTERN AVE., SUITE 136, TORRANCE CA 90501
Yutaka Niihara	director, 10 percent owner, officer: Chairman and CEO	20725 S. WESTERN BLVD., SUITE 136, TORRANCE CA 90501
Lori Teranishi	director	1000 BISHOP STREET, SUITE 500, HONOLULU HI 96813
Charles William Stark	officer: SVP, Clinical Development	21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE CA 90503
George Sekulich	officer: CIO & SVP	21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE CA 90503
Lui Alfred Fu Kong	director	21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE CA 90503
Jane Pine Wood	director	956 MAIN STREET, DENNIS MA 02638
Wei Peu Zen	director	21250 HAWTHORNE BLVD., SUITE 800, TORRANCE CA 90503
Sherwood Joseph Charles Iii	officer: Chief Financial Officer	21250 HAWTHORNE BLVD., SUITE 800, TORRANCE CA 90503
Masaharu Osato	director	3440 LOMITA BOULEVARD, SUITE 320, TORRANCE CA 90505
Ian Harvey Zwicker	director	21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE CA 90503
Lan T. Tran	officer: Chief Administrative Officer	20725 S. WESTERN AVE., SUITE 136, TORRANCE CA 90501
Robert Iv Dickey	director	320 WEST MERMAID LANE, PHILADELPHIA PA 19118
Yasushi Nagasaki	officer: Sr. VP Finance	20725 S. WESTERN AVE., SUITE 136, TORRANCE CA 90501